The Medical Research Council Trial.
نویسنده
چکیده
THE medical literature over the past half dozen or more years has been strewn with reports and commentaries on the treatment of mild hypertension. Those who are particularly influenced by the evidence from the insurance companies point to the well-documented increased mortality in the presence of even a little high blood pressure, cite the efficacy of lowering blood pressure by various nonpharmacological and pharmacological means, and urge public education and individual and mass intervention. Others, though not doubting the actuarial data, have not been reluctant to express different views; they have pointed to the limitations of and uncertainties in the findings from the various clinical trials to date and said, "Go slow." Characteristic of the contrary stands are the comments by Frohlich: "We should still consider that all individuals whose diastolic blood pressure exceeds 90 mm Hg are at increased cardiovascular risk. Moreover, we must still recognize that in these individuals pressure should be reduced in order to minimize that risk." And the comments by Kaplan: "We must not lose sight of the admonition that therapy of asymptomatic hypertension is preventive therapy, not curative. Further, only a minority of hypertensive patients will be saved from disease and death by such therapy. We should do nothing that will add any degree of risk, be it ever so small, to the large majority of mild hypertensive patients who would not suffer if left untreated." It was hoped that the results of the recent Medical Research Council (MRC) Trial might at least partially resolve the controversy. In brief, the MRC Trial was a clinical trial of drug treatment of mild hypertension (baseline systolic pressure less than 100 mm Hg; diastolic pressure, 90-109 mm Hg). The trial included 17,354 subjects aged 35 to 64 years who were observed for an average of 5'/2 years. Nearly all were white, and the division between the sexes was almost equal. Most of these participants were members of general practice clinics mainly located in small towns. Excluded were patients already receiving antihypertensive treatment, those known to have diabetes, gout, asthma, angina pectoris, or intermittent claudication, and those who had experienced a recent myocardial infarction or stroke. The trial, which was single blind, provided for random allocation of the participants to four schedules: treatment with a fixed dose (10 mg daily) of a thiazide diuretic (bendrofluazide) or a similar looking placebo, and treatment with graded daily doses up to 240 mg of a /3-blocking drug (propranolol) or a similar appearing placebo. No specific advice was given regarding salt intake, obesity, exercise, or smoking. Treatment with active drugs resulted in substantial drops in blood pressure that were
منابع مشابه
Response to the commentary of Segrot et al on the Swedish SFP trial.
The authors are currently conducting a randomized controlled trial of the Strengthening Families Programme 10-14 (UK) (SFP 10-14 UK), funded by the National Prevention Research Initiative (http:// www.npri.org.uk). The NPRI funding partners are Alzheimer’s Research Trust; Alzheimer’s Society; Biotechnology and Biological Sciences Research Council; British Heart Foundation; Cancer Research UK; C...
متن کاملCommentary: the 1944 patulin trial: the first properly controlled multicentre trial conducted under the aegis of the British Medical Research Council.
The 1948 report of the British Medical Research Council's randomized trial of streptomycin for pulmonary tuberculosis is widely regarded as marking the beginning of the modern history of controlled clinical trials. Four years earlier, however, a methodologically sophisticated multicentre trial conducted under the aegis of the Medical Research Council was reported, which assessed the effects of ...
متن کاملThe UK Medical Research Council and clinical trials, 1934-1960
1940-1949: Randomised controlled trial design pioneered MRC scientists developed what is today the gold standard for clinical trial design while testing streptomycin to treat pulmonary tuberculosis. Although the MRC failed to make any substantive contribution to the development of trial methods before the 1940s, it made exceptionally important contributions between 1944 and 1960. Surprisingly, ...
متن کاملWorking to build a healthy Australia: A new era for the NHMRC.
The National Health and Medical Research Council Act 1992 (Cwlth) was amended in 2006 to streamline governance arrangements and help the National Health and Medical Research Council (NHMRC) to become a more responsive organisation and more effective at both acquisition and implementation of new knowledge. As part of the NHMRC's plans for the future, we will implement the recommendations of the ...
متن کاملThe clinical significance of positive cultures and of isoniazid-resistant tubercle bacilli during the treatment of pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council.
Within a few months of the introduction of isoniazid (isonicotinic acid hydrazide) in the treatment of pulmonary tuberculosis, reports appeared of the frequent and rapid emergence of isoniazidresistant bacteria when the drug was used alone (Medical Research Council, 1952; Ferebee and Long, 1953; Lotte and Poussier, 1953; U.S. Veterans Administration, 1953). In view of earlier experience with st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Hypertension
دوره 8 9 شماره
صفحات -
تاریخ انتشار 1986